PITX1 is a novel predictor of the response to chemotherapy in head and neck squamous cell carcinoma

Takenobu,Masao; Osaki,Mitsuhiko; Fujiwara,Kazunori; Fukuhara,Takahiro; Kitano,Hiroya; Kugoh,Hiroyuki; Okada,Futoshi

doi:10.3892/mco.2016.880

PITX1 is a novel predictor of the response to chemotherapy in head and neck squamous cell carcinoma

Authors:
- Masao Takenobu
- Mitsuhiko Osaki
- Kazunori Fujiwara
- Takahiro Fukuhara
- Hiroya Kitano
- Hiroyuki Kugoh
- Futoshi Okada
View Affiliations

Affiliations: Department of Otolaryngology, Head and Neck Surgery, Faculty of Medicine, Tottori University, Yonago, Tottori 683‑8503, Japan, Division of Pathological Biochemistry, Department of Biomedical Sciences, Faculty of Medicine, Tottori University, Yonago, Tottori 683‑8503, Japan, Chromosome Engineering Research Center, Tottori University, Yonago, Tottori 683‑8503, Japan
Published online on: April 28, 2016 https://doi.org/10.3892/mco.2016.880
Pages: 89-94

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The pituitary homeobox 1 (PITX1) protein is essential for developmental processes in humans. Previously, PITX1 was identified as a possible tumor suppressor gene in various types of human carcinoma. However, the association between PITX1 and human head and neck squamous cell carcinoma (HNSCC) remains to be elucidated. Immunohistochemical analysis was performed to examine the expression levels of PITX1 in 47 cases of HNSCC, and in 4 control cases. The expression of p53 was also examined in these cases. The labeling indices (LIs) were calculated, and the correlations between clinical factors (chemosensitivity, prognosis and the degree of differentiation) and the LIs were assessed. The PITX1 LI in HNSCC was 27.4±14.5%, which was significantly lower compared with the LIs of the control samples: 76.9±6.97% (P<0.05). Additionally, the PITX1 LIs were 39.9±6.2, 26.9±16.9 and 24.2±11.8% in the complete response (CR), partial response (PR), stable disease or progressive disease (SD/PD) groups, respectively. The PITX1 LI in the CR group revealed the highest result between the all groups, and it was significantly greater compared with that in the SD/PD group (P<0.01). The p53 LIs were 24.5±19.9, 25.7±16.9 and 19.8±13.8 in the CR, PR and SD/PD groups, respectively (P>0.05). Neither the PITX1 nor the p53 LIs were a statistically significant indicator of the prognosis. PITX1 is a candidate tumor suppressor gene and a possible predictive biomarker of chemosensitivity of human HNSCC.

View Figures

View References

1.	Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249. 2009. View Article : Google Scholar : PubMed/NCBI
2.	Al-Sarraf M: Treatment of locally advanced head and neck cancer: Historical and critical review. Cancer Control. 9:387–399. 2002.PubMed/NCBI
3.	Seiwert TY and Cohen EEW: State-of-the-art management of locally advanced head and neck cancer. Br J Cancer. 92:1341–1348. 2005. View Article : Google Scholar : PubMed/NCBI
4.	Urba S, Wolf G, Eisbruch A, Worden F, Lee J, Bradford C, Teknos T, Chepeha D, Prince M, Hogikyan N and Taylor J: Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: A new treatment paradigm. J Clin Oncol. 24:593–598. 2006. View Article : Google Scholar : PubMed/NCBI
5.	Lamonerie T, Tremblay JJ, Lanctôt C, Therrien M, Gauthier Y and Drouin J: Ptx1, a bicoid-related homeo box transcription factor involved in transcription of the pro-opiomelanocortin gene. Genes Dev. 10:1284–1295. 1996. View Article : Google Scholar : PubMed/NCBI
6.	DeLaurier A, Schweitzer R and Logan M: Pitx1 determines the morphology of muscle, tendon and bones of the hindlimb. Dev Biol. 299:22–34. 2006. View Article : Google Scholar : PubMed/NCBI
7.	Kolfschoten IGM, van Leeuwen B, Berns K, Mullenders J, Beijersbergen RL, Bernards R, Voorhoeve PM and Agami R: A genetic screen identifies PITX1 as a suppressor of RAS activity and tumorigenicity. Cell. 121:849–858. 2005. View Article : Google Scholar : PubMed/NCBI
8.	Qi DL, Ohhira T, Fujisaki C, Inoue T, Ohta T, Osaki M, Ohshiro E, Seko T, Aoki S, Oshimura M and Kugoh H: Identification of PITX1 as a TERT suppressor gene located on human chromosome 5. Mol Cell Biol. 31:1624–1636. 2011. View Article : Google Scholar : PubMed/NCBI
9.	Libório TN, Acquafreda T, Matizonkas-Antonio LF, Silva-Valenzuela MG, Ferraz AR and Nunes FD: In situ hybridization detection of homeobox genes reveals distinct expression patterns in oral squamous cell carcinomas. Histopathology. 58:225–233. 2011. View Article : Google Scholar : PubMed/NCBI
10.	Osaki M, Chinen H, Yoshida Y, Ohhira T, Sunamura N, Yamamoto O, Ito H, Oshimura M and Kugoh H: Decreased PITX1 gene expression in human cutaneous malignant melanoma and its clinicopathological significance. Eur J Dermatol. 23:344–349. 2013.PubMed/NCBI
11.	Lord RV, Brabender J, Wickramasinghe K, DeMeester SR, Holscher A, Schneider PM, Danenberg PV and DeMeester TR: Increased CDX2 and decreased PITX1 homeobox gene expression in Barrett's esophagus and Barrett's-associated adenocarcinoma. Surgery. 138:924–931. 2005. View Article : Google Scholar : PubMed/NCBI
12.	Chen YN, Chen H, Xu Y, Zhang X and Luo Y: Expression of pituitary homeobox 1 gene in human gastric carcinogenesis and its clinicopathological significance. World J Gastroenterol. 14:292–297. 2008. View Article : Google Scholar : PubMed/NCBI
13.	Chen Y, Knösel T, Ye F, Pacyna-Gengelbach M, Deutschmann N and Petersen I: Decreased PITX1 homeobox gene expression in human lung cancer. Lung Cancer. 55:287–294. 2007. View Article : Google Scholar : PubMed/NCBI
14.	Stender JD, Stossi F, Funk CC, Charn TH, Barnett DH and Katzenellenbogen BS: The estrogen-regulated transcription factor PITX1 coordinates gene-specific regulation by estrogen receptor-alpha in breast cancer cells. Mol Endocrinol. 25:1699–1709. 2011. View Article : Google Scholar : PubMed/NCBI
15.	Calvisi DF, Ladu S, Conner EA, Seo D, Hsieh JT, Factor VM and Thorgeirsson SS: Inactivation of Ras GTPase-activating proteins promotes unrestrained activity of wild-type Ras in human liver cancer. J Hepatol. 54:311–319. 2011. View Article : Google Scholar : PubMed/NCBI
16.	Knösel T, Chen Y, Hotovy S, Settmacher U, Altendorf-Hofmann A and Petersen I: Loss of desmocollin 1–3 and homeobox genes PITX1 and CDX2 are associated with tumor progression and survival in colorectal carcinoma. Int J Colorectal Dis. 27:1391–1399. 2012. View Article : Google Scholar : PubMed/NCBI
17.	Kwok SC, Liu XM, Mangel P and Daskal I: PTX1 (ERGIC2)-VP22 fusion protein upregulates interferon-beta in prostate cancer cell line PC-3. DNA Cell Biol. 25:523–529. 2006. View Article : Google Scholar : PubMed/NCBI
18.	Somers KD, Merrick MA, Lopez ME, Incognito LS, Schechter GL and Casey G: Frequent p53 mutations in head and neck cancer. Cancer Res. 52:5997–6000. 1992.PubMed/NCBI
19.	Poeta M, Manola J, Goldwasser MA, Forastiere A, Benoit N, Califano JA, Ridge JA, Goodwin J, Kenady D, Saunders J, et al: TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med. 357:2552–2561. 2007. View Article : Google Scholar : PubMed/NCBI
20.	Warnakulasuriya S, Jia C, Johnson N and Houghton J: p53 and P-glycoprotein expression are significant prognostic markers in advanced head and neck cancer treated with chemo/radiotherapy. J Pathol. 191:33–38. 2000. View Article : Google Scholar : PubMed/NCBI
21.	Mannarini L, Bertino G, Morbini P, Villa C and Benazzo M: Markers of chemoradiation resistance in patients with locally advanced head and neck squamous cell carcinoma, treated by intra-arterial carboplatin and concurrent radiation. Acta Otorhinolaryngol Ital. 27:173–180. 2007.PubMed/NCBI
22.	Temam S, Flahault A, Périé S, Monceaux G, Coulet F, Callard P, Bernaudin JF, St Guily JL and Fouret P: P53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck. J Clin Oncol. 18:385–394. 2000.PubMed/NCBI
23.	Okumura K, Hasegawa Y, Harada H, Ishizaki K and Murakami S: A comparative study of p53 status and clinical response to chemotherapy in head and neck cancer. Nagoya Med J. 46:171–180. 2003.
24.	Szentkúti G, Dános K, Brauswetter D, Kiszner G, Krenács T, Csákó L, Répássy G and Tamás L: Correlations between prognosis and regional biomarker profiles in head and neck squamous cell carcinomas. Pathol Oncol Res. 21:643–650. 2015. View Article : Google Scholar : PubMed/NCBI
25.	Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweji J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guldelines to evaluate the response to treatment in solod tumors. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
26.	Nakashima T, Maehara Y, Kohnoe S, Hayashi I and Katsuta Y: Histologic differentiation and chemosensitivity of human head and neck squamous cell carcinomas. Head Neck. 12:406–410. 1990. View Article : Google Scholar : PubMed/NCBI
27.	Hoffmann TK, Sonkoly E, Hauser U, van Lierop A, Whiteside TL, Klussmann JP, Hafner D, Schuler P, Friebe-Hoffmann U, Scheckenbach K, et al: Alterations in the p53 pathway and their association with radio- and chemosensitivity in head and neck squamous cell carcinoma. Oral Oncol. 44:1100–1109. 2008. View Article : Google Scholar : PubMed/NCBI
28.	Hoa M, Davis SL, Ames SJ and Spanjaard RA: Amplification of wild-type K -ras promotes growth of head and neck squamous. Cancer Res. 62:7154–7156. 2002.PubMed/NCBI
29.	Blagoev KB: Cell proliferation in the presence of telomerase. PLoS One. 4:e46222009. View Article : Google Scholar : PubMed/NCBI
30.	Ohira T, Naohiro S, Nakayama Y, Osaki M, Okada F, Oshimura M and Kugoh H: miR-19b regulates hTERT mRNA expression through targeting PITX1 mRNA in melanoma cells. Sci Rep. 5:82012015. View Article : Google Scholar : PubMed/NCBI
31.	Ueda Y, Hiyama E, Kamimatsuse A, Kamei N, Ogura K and Sueda T: Wnt signaling and telomerase activation of hepatoblastoma: Correlation with chemosensitivity and surgical resectability. J Pediatr Surg. 46:2221–2227. 2011. View Article : Google Scholar : PubMed/NCBI
32.	Wang L, Li PF, Geng M, Cao YC and Yin YC: Correlation between chemosensitivity to anticancer drugs and telomerase reverse transcriptase mRNA expression in gastric cancer. Diagn Pathol. 8:332013. View Article : Google Scholar : PubMed/NCBI
33.	Guo X, Wang W, Zhou F, Lu Z, Fang R, Jia F, Bu X, Li R, Zhang B, Wu M and Wei L: siRNA-mediated inhibition of hTERT enhances chemosensitivity of hepatocellular carcinoma. Cancer Biol Ther. 7:1555–1560. 2008. View Article : Google Scholar : PubMed/NCBI